Recent Updates
Recently added Catalysts
BWAY Positive Sentiment

Efficacy and Safety of Deep Transcranial Magnetic Stimulation Versus High-Frequency Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder: A Systematic Review

Key Takeaway: This systematic review compares the efficacy and safety of deep transcranial magnetic stimulation (dTMS) and high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) for major depressive disorder (MDD). The findings indicate that dTMS has a higher overall antidepressant response rate (60.0%) compared to HF-rTMS (41.7%). While dTMS is associated with more muscle-related side effects, both treatments maintain favorable safety profiles. The review calls for more rigorous studies to validate these results.
Price reaction · baseline $4.705 (2024-10-10 close) · hit pre-market · 1 other BWAY headline(s) in the window, move may be shared
day 0 close · peak
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • dTMS shows a significantly higher antidepressant response rate.
  • Both treatments have favorable safety profiles.
  • The study is based on high-quality randomized controlled trials.

CONCERNS & RISKS

  • dTMS causes more muscle twitching/spasms or jaw pain incidences.
  • Further rigorous RCTs are needed to confirm findings.

Full Press Release Details

Background:
This systematic review aimed to evaluate and compare the safety and effectiveness of deep transcranial magnetic stimulation ( dTMS ) with high-frequency repetitive transcranial magnetic stimulation ( HF-rTMS ) for individuals diagnosed with major depressive disorder ( MDD ) . The study was motivated by the inconsistent findings of prior studies comparing dTMS and HF-rTMS for depression treatment. The researchers hypothesized that dTMS would yield a significantly higher response rate than HF-rTMS in adult patients with MDD .
Objective:
The objective of this systematic review was to evaluate and compare the safety and effectiveness of dTMS with that of high-frequency rTMS (HF- rTMS ; ≥10 Hz) in individuals diagnosed with major depressive disorder (MDD).
Methods:
The review searched Chinese and English databases for RCTs comparing dTMS and HF-rTMS . The overall antidepressant response and remission rates were the co-primary outcomes. The systematic review included two RCTs that compared the efficacy and safety of dTMS versus HF-rTMS for treating MDD in adults.
Results:
Two RCTs met the inclusion criteria, with a Jadad score of ≥ 3, indicating high quality. The overall antidepressant response rate was significantly higher in the dTMS group (60.0%) than in the HF-rTMS group (41.7%). The results of this systematic review showed that dTMS provides a more pronounced overall antidepressant response than HF-rTMS , but causes more muscle twitching/spasms or jaw pain incidences. Both RCTs had similar rates of other adverse events and discontinuation.
Conclusions:
dTMS leads to a better antidepressant response than HF-rTMS , although both interventions have favorable safety profiles. However, more RCTs using rigorous methodologies are warranted. The conclusions of this systematic review are that dTMS is associated with a better antidepressant response than HF-rTMS in adult patients with MDD , although both treatment modalities have favorable safety profiles.

Frequently Asked Questions

What is the main finding of the review?

The review found that dTMS has a significantly higher antidepressant response rate than HF-rTMS.

What were the safety profiles of dTMS and HF-rTMS?

Both dTMS and HF-rTMS have favorable safety profiles, although dTMS caused more muscle-related side effects.

How many RCTs were included in the review?

The review included two randomized controlled trials (RCTs) that met the inclusion criteria.

What is the significance of the Jadad score?

A Jadad score of ≥3 indicates that the included RCTs were of high quality.

What further research is suggested?

The review suggests that more rigorous randomized controlled trials are needed to confirm the findings.

Last updated: Oct 11, 2024